Michael Kauffman

Dr. Michael G.
Kauffman is a President, Chief Executive Officer & Director at Nereid Therapeutics, Inc., a Non-Executive Chairman at BiVictriX Therapeutics Plc and a Director & President-Development at Verastem, Inc. He is on the Board of Directors at Kyntra Bio, Inc., Nereid Therapeutics, Inc., Verastem, Inc., FoRx Therapeutics AG, Incendia Therapeutics, Inc. and Mirror Biologics Inc. Dr. Kauffman was previously employed as an Independent Director by Adicet Bio, Inc., an Independent Director by Infinity Pharmaceuticals, Inc., an Independent Director by Kezar Life Sciences, Inc., a Chief Medical Officer by Onyx Pharmaceuticals, Inc., an Advisor by Bessemer Venture Partners LP, a Chief Medical Officer by Proteolix, Inc., a President & Chief Executive Officer by EPIX Pharmaceuticals, Inc., a Vice President-Clinical by Takeda Oncology Co., a Medical Director by Biogen Idec, Inc., a Vice President-Medicine by Millennium Predictive Medicine, Inc., a President & Chief Executive Officer by Predix Pharmaceuticals, Inc., an Advisor by Prime Movers Lab LLC, and an Executive Vice President-Distribution Operations by The Jones Group, Inc. He also served on the board at Metamark Genetics, Inc., Karyopharm Therapeutics, Inc., CombinatoRx, Inc., Zalicus, Inc. and Excision BioTherapeutics, Inc. He received his undergraduate degree from Amherst College and a doctorate degree from The Johns Hopkins University School of Medicine.